Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

EYEGET

Financiado

Gene therapy of inherited retinal diseases

Inherited retinal degenerations (IRDs) are a major cause of blindness worldwide. IRD patients witness inexorable progressive vision loss as no therapy is currently available. In the last decade my group has significantly contribut... ver más

31/12/2022

FONDAZIONE TELETHO...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

FONDAZIONE TELETHON ETS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-ADG-2015: ERC Advanced Grant

I+D

Cerrada hace 9 años

0% 100% 100%

4 Participantes

FONDAZIONE TELETHON ETS

2.36M€ | Lider

SANDOZ INDUSTRIAL PRODUCTS

INNOVAVECTOR SRL

N.D. | Participante

Proyectos interesantes

CNS2023-144370 Herramientas diagnósticas, pronósticas y terapéuticas 200K€ Cerrado

GeneVision Developing a cure for retinitis pigmentosa due to Usher synd... 150K€ Cerrado

ProgRet European Training Program to Understand, Diagnose and Treat... 3M€ Cerrado

PDC2022-133960-I00 DESARROLLO DE UNA POTENCIAL TERAPIA INMUNOMODULADORA PARA LA... 150K€ Cerrado

CombGeneTher Gene-Independent Combination Therapy for Rod-Cone Dystrophy 212K€ Cerrado

PID2019-106230RB-I00 TERAPIA CON CRISPR Y NEUROPROTECCION EN DISTROFIAS HEREDITAR... 167K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 76 meses Fecha Inicio: 2016-08-31
Fecha Fin: 2022-12-31

Líder del proyecto

FONDAZIONE TELETHON ETS

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Inherited retinal degenerations (IRDs) are a major cause of blindness worldwide. IRD patients witness inexorable progressive vision loss as no therapy is currently available. In the last decade my group has significantly contributed to a change of this scenario by developing efficient adeno-associated viral (AAV) vectors for retinal gene therapy that are safe and effective in humans. The objective of EYEGET (EYE GEne Therapy) is to overcome some of the current major limitations in the field of retinal gene therapy to expand initial therapeutic successes to a larger number of IRDs. To achieve this, we propose to use four parallel, highly innovative and complementary approaches: i. expansion of the limited AAV cargo capacity by a novel methodology based on co-administration of multiple AAVs that reassemble in target retinal cells and reconstitute large genes; ii. targeting of frequent dominant gain-of-function mutations that cause RP using state-of-the-art AAV-mediated genome editing technologies; iii. induction of retinal cells clearance of toxic IRD products by AAV-mediated activation of autophagy and lysosomal function; iv. development of methodologies to directly convert fibroblasts to photoreceptors that can be transplanted in retinas from IRD patients with advanced PR loss and for whom in vivo gene therapy is no longer an option. We will use a combination of in vitro and in vivo state-of-the-art technologies including novel AAV vector design, high content screening of drugs that enhance AAV transduction, genome editing, and advanced in vivo retinal phenotyping to obtain proof-of-concept for each of these therapeutic strategies. The results from this study may impact the quality of life of millions of people worldwide by providing a cure based on gene and/or cell therapy for a large group of IRDs.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores